With a patient-centered approach, our mission is to offer patients comprehensive care of their renal diseases, based on effective therapeutic options supported by accurate diagnosis and advanced prognosis tools.
Projects in development are specifically dedicated to proposing alternative treatments for patients suffering from renal diseases but also developing reliable biomarkers or tools to facilitate the diagnosis and assess treatment outcomes to improve the overall management of a patient.
AVEROA entered into two major agreements
with AKEBIA Therapeutics, Inc. [AKBA], a US-based company that granted AVEROA to develop and commercialize AVA1014 in Europe, UK, Switzerland and Turkey.
Research collaboration and license agreement with IDIBELL for the development of a biomarker and a new treatment for renal lithiasis.
President & CEO - Medical Director
Chief Financial Officer
Chief Operating Officer
Regulatory Affairs Manager
Business Development Director
Pharmaceutical Development Manager
Clinical-Regulatory Advisor
Identify and develop treatments where science can be applied in new ways of treating diseases with high medical needs.
Value-based health care is about putting the patient at the center to produce the best outcomes.
Develop efficient drugs for patients in a smart and quick way.
Science has become a team activity. We recognize its complexity and help innovative drugs reach their next step of development
submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of AVA1014 for Treating Complications Associated with Chronic Kidney Disease.
